» Articles » PMID: 15313118

Cellular and Molecular Mechanisms of Pulmonary Vascular Remodeling: Role in the Development of Pulmonary Hypertension

Overview
Journal Microvasc Res
Date 2004 Aug 18
PMID 15313118
Citations 105
Authors
Affiliations
Soon will be listed here.
Abstract

Pulmonary artery vasoconstriction and vascular remodeling greatly contribute to a sustained elevation of pulmonary vascular resistance (PVR) and pulmonary arterial pressure (PAP) in patients with pulmonary arterial hypertension (PAH). The development of PAH involves a complex and heterogeneous constellation of multiple genetic, molecular, and humoral abnormalities, which interact in a complicated manner, presenting a final manifestation of vascular remodeling in which fibroblasts, smooth muscle and endothelial cells, and platelets all play a role. Vascular remodeling is characterized largely by medial hypertrophy due to enhanced vascular smooth muscle cell proliferation or attenuated apoptosis and to endothelial cell over-proliferation, which can result in lumen obliteration. In addition to other factors, cytoplasmic Ca2+ in particular seems to play a central role as it is involved in both the generation of force through its effects on the contractile machinery, and the initiation and propagation of cell proliferation via its effects on transcription factors, mitogens, and cell cycle components. This review focuses on the role played by cellular factors, circulating factors, and genetic molecular signaling factors that promote a proliferative, antiapoptotic, and vasoconstrictive physiological milieu leading to vascular remodeling.

Citing Articles

mTOR in the Development of Hypoxic Pulmonary Hypertension Associated with Cardiometabolic Risk Factors.

Flores K, Almeida C, Arriaza K, Pena E, El Alam S Int J Mol Sci. 2024; 25(20).

PMID: 39456805 PMC: 11508063. DOI: 10.3390/ijms252011023.


Design and comprehensive characterization of dry powder inhalation aerosols of simvastatin DPPC/DPPG lung surfactant-mimic nanoparticles/microparticles for pulmonary nanomedicine.

Encinas-Basurto D, Acosta M, Eedara B, Fineman J, Black S, Mansour H RSC Adv. 2024; 14(40):29413-29427.

PMID: 39285876 PMC: 11404307. DOI: 10.1039/d4ra04947k.


Regulated vascular smooth muscle cell death in vascular diseases.

Yin Z, Zhang J, Shen Z, Qin J, Wan J, Wang M Cell Prolif. 2024; 57(11):e13688.

PMID: 38873710 PMC: 11533065. DOI: 10.1111/cpr.13688.


Identification of Serum Interleukin-22 as Novel Biomarker in Pulmonary Hypertension: A Translational Study.

Klein F, Dinesh S, Fiedler D, Grun K, Schrepper A, Bogoviku J Int J Mol Sci. 2024; 25(7).

PMID: 38612795 PMC: 11012889. DOI: 10.3390/ijms25073985.


Reversal of Pulmonary Hypertension in a Human-Like Model: Therapeutic Targeting of Endothelial DHFR.

Murugesan P, Zhang Y, Huang Y, Zong N, Youn J, Chen W Circ Res. 2024; 134(4):351-370.

PMID: 38299369 PMC: 10880947. DOI: 10.1161/CIRCRESAHA.123.323090.